Clinical study for 'Yi-Qin-Fang' decoction in the treatment of uric acid nephropathy by high colon pathway

Not Applicable

• Conditions: ric acid nephropathy

• Registration Number: ITMCTR1900002859
• Lead Sponsor: Shenzhen Second People's Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Diagnostic criteria: meet the diagnostic criteria for uric acid nephropathy;
2. Patients belonging to stage 1-4 of chronic kidney disease;
3. Aged 16 to 78 years old;
4. Patients who accepted the study and agreed to sign the informed consent, who can cooperate on time;
5. TCM syndrome classification and quantitative basis: refer to the 'Guiding Principles for Clinical Research of New Chinese Medicines' and 'Diagnosis, Syndrome Differentiation, and Efficacy Determination of Uric Acid Nephropathy' specified by the Nephrology Branch of the Chinese Traditional Medicine Association in 2008, which belongs to the spleen and kidney Qi deficiency, liver and kidney yin deficiency, qi and yin deficiency, dampness and turbidity, and blood stasis syndrome;
6. Those who did not take Chinese medicine, western medicine or uric acid lowering drug 2 weeks before the test, or those who used the drug but stopped using it for more than 2 weeks;
7. Long-term use of hydrochlorothiazide and other drugs that have an effect on blood uric acid, and can be used instead of other drugs, 2 weeks after the drug is discontinued and changed.

Exclusion Criteria

1. with stage CKD5, renal damage caused by other reasons, or secondary hyperuricemia;
2. The syndrome differentiation of TCM belongs to the deficiency of spleen and kidney, and the deficiency of yin and yang;
3. taking other drugs that affect kidney function;
4. Patients with acute severe infection;
5. Patients with severe colorectal diseases such as hemorrhoids and anal fistula;
6. Patients with severe primary diseases such as heart, kidney, liver, brain, and hematopoietic system, who are in acute exacerbation stage;
7. Women during pregnancy or lactation;
8. Those who are allergic to allopurinol or have positive HLA-B 5801 gene test;
9. Disagree or disagree with the researchers.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
C-reactive protein;cystatin C;Blood urea nitrogen;TNF-alpha;glomerular filtration rate;Homocysteine;Blood routine;Uric acid;Urine routine;24 hour urine protein quantification;Serum creatinine;

Secondary Outcome Measures

Name	Time	Method
-acetyl-beta-D-glucosidase;Urine osmotic pressure;